Publication: The effect of 0.25% apraclonidine in preventing intraocular pressure elevation after Nd : YAG laser posterior capsulotomy
dc.contributor.author | Şimşek, Şaban | |
dc.contributor.author | Demirok, Ahmet | |
dc.contributor.author | Çınar, Adnan | |
dc.contributor.author | Yaşar, Tekin | |
dc.contributor.buuauthor | Ertürk, Haluk | |
dc.contributor.buuauthor | Karadenizli, Caner | |
dc.contributor.department | Tıp Fakültesi | |
dc.contributor.department | Göz Hastalıkları Ana Bilim Dalı | |
dc.contributor.scopusid | 7003716972 | |
dc.contributor.scopusid | 6503909861 | |
dc.date.accessioned | 2021-10-07T07:22:47Z | |
dc.date.available | 2021-10-07T07:22:47Z | |
dc.date.issued | 1998 | |
dc.description.abstract | Purpose. The efficacy and adverse effects of 0.25% apraclonidine on intraocular pressure (IOP) after Nd: YAG laser posterior capsulotomy were investigated, and the results were compared with placebo, 0.50% timolol maleate and 1% apraclonidine. Methods. Eighty eyes were randomly assigned to four groups of 20 eyes. In a double-masked design, the groups were treated with placebo (group I), 0.50% timolol maleate (group 2), 1% apraclonidine (group 3), 0.25% apraclonidine (group 4) one hour before and five minutes after Nd:YAG laser posterior capsulotomy. IOP was measured by applanation tonometry I hour before (baseline IOP) and 1, 3, 24 hours after capsulotomy. Results. The average baseline IOP increased respectively 3.90 +/- 5.35, 5.95 +/- 5.32, 1.15 +/- 3.20 mmHg in the first group 1, 3 and 24 hours post-treatment. There were significant differences between baseline IOP and 1 and 3 hours but not at 24 hours (p=0.004, p=0.001, p=0.13). IOP increased 0.40 +/- 4.08, 0.75 +/- 5.33, 0.80 +/- 6.03 mmHg in the second group at the same times. The differences between the average baseline IOP and the 1, 3 and 24 h measurement were not significant (p=0.83, p=0.65, p=0.93). In the third group, IOP decreased 3.70 +/- 2.40, 3.30 +/- 2.47, 2.65 +/- 1.56 mmHg at the measurement times, with significant differences between the average baseline IOP and the 1, 3 and 24 hour measurements (p=0.001, p=0.0001, p=0.01). In the fourth group IOP increased 0.35 +/- 3.32 mmHg at 1 hour, but decreased 1.25 +/- 3.41, 0.90 +/- 2. 07 mmHg at 3 and 24 hours. The differences were not significant (p = 0.94, p = 0.16, p = 0.08). When the 0.25% and 1% apraclonidine groups were compared, there were significant differences between the average IOP at 1 hour in both groups but not at 3 and 24 hours (p=0.01, p = 0.17, p = 0.21). Similarly, there were no significant differences between the average IOP at the same times when the 0.25% apraclonidine group was compared with the timolol group (p = 0.30, p = 0.08, p = 0.16). Some systemic and local side effects were seen in the timolol and 1% apraclonidine groups, but none with 0.25% apraclonidine. Conclusions. It was concluded that 0.25% apraclonidine is effective in preventing the early elevation of IOP after Nd:YAG laser posterior capsulotomy and may offer an alternative to 0.50% timolol maleate and 1% apraclonidine. | |
dc.identifier.citation | Şimşek, S. vd. (1998). "The effect of 0.25% apraclonidine in preventing intraocular pressure elevation after Nd : YAG laser posterior capsulotomy". European Journal of Ophthalmology, 8(3), 167-172. | |
dc.identifier.endpage | 172 | |
dc.identifier.issn | 1120-6721 | |
dc.identifier.issue | 3 | |
dc.identifier.pubmed | 9793771 | |
dc.identifier.scopus | 2-s2.0-0031715452 | |
dc.identifier.startpage | 167 | |
dc.identifier.uri | https://doi.org/10.1177/112067219800800309 | |
dc.identifier.uri | https://journals.sagepub.com/doi/pdf/10.1177/112067219800800309 | |
dc.identifier.uri | http://hdl.handle.net/11452/22259 | |
dc.identifier.volume | 8 | |
dc.identifier.wos | 000077895200009 | |
dc.indexed.wos | SCIE | |
dc.language.iso | en | |
dc.publisher | Sage Publications | |
dc.relation.collaboration | Yurt içi | |
dc.relation.journal | European Journal of Ophthalmology | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Ophthalmology | |
dc.subject | Nd : YAG laser | |
dc.subject | Posterior capsulotomy | |
dc.subject | Apraclonidine | |
dc.subject | Timolol maleate | |
dc.subject | 1-percent apraclonidine | |
dc.subject | Dose-response | |
dc.subject | Neodymium | |
dc.subject | Timolol | |
dc.subject | Rise | |
dc.subject | Eyes | |
dc.subject.emtree | Apraclonidine | |
dc.subject.emtree | Timolol maleate | |
dc.subject.emtree | Adult | |
dc.subject.emtree | Aged | |
dc.subject.emtree | Anxiety | |
dc.subject.emtree | Article | |
dc.subject.emtree | Bronchospasm | |
dc.subject.emtree | Capsulotomy | |
dc.subject.emtree | Clinical trial | |
dc.subject.emtree | Controlled clinical trial | |
dc.subject.emtree | Controlled study | |
dc.subject.emtree | Double blind procedure | |
dc.subject.emtree | Drug efficacy | |
dc.subject.emtree | Early diagnosis | |
dc.subject.emtree | Female | |
dc.subject.emtree | Human | |
dc.subject.emtree | Human cell | |
dc.subject.emtree | Human tissue | |
dc.subject.emtree | Intraocular pressure abnormality | |
dc.subject.emtree | Major clinical study | |
dc.subject.emtree | Male | |
dc.subject.emtree | Neodymium laser | |
dc.subject.emtree | Phacoemulsification | |
dc.subject.emtree | Priority journal | |
dc.subject.emtree | Punctate keratitis | |
dc.subject.scopus | Capsule Opacification; Phakic Intraocular Lenses; Capsulotomy | |
dc.subject.wos | Ophthalmology | |
dc.title | The effect of 0.25% apraclonidine in preventing intraocular pressure elevation after Nd : YAG laser posterior capsulotomy | |
dc.type | Article | |
dspace.entity.type | Publication | |
local.contributor.department | Tıp Fakültesi/Göz Hastalıkları Ana Bilim Dalı | |
local.indexed.at | Scopus | |
local.indexed.at | WOS |
Files
License bundle
1 - 1 of 1
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: